Abstract
Chronic graft-versus-host disease (GVHD) refractory to standard immunosuppressive therapy remains a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). Thalidomide may be effective in some patients with high-risk or refractory chronic GVHD. We report a single-institution study of thalidomide in 37 BMT patients with extensive chronic GVHD refractory to standard immunosuppressive therapy. Acute GVHD occurred in 34 (91%) of patients and evolved progressively into chronic GVHD in 23 (62%) patients. Thalidomide was added to standard immunosuppressive therapy a median of 11 months (range 0–105 months) after the diagnosis of chronic GVHD. Fourteen of 37 (38%) patients responded after introduction of thalidomide (one complete, 13 partial). Ten of 21 (46%) children and four of 16 (25%) adults responded. Responses were seen in eight of 17 (47%) recipients of related donor marrow and six of 20 (30%) recipients of unrelated donor marrow. Eight of 23 (34%) patients with progressive onset of chronic GVHD showed a response. There were no deaths among the responders. The remaining 23 patients (62%) did not respond and of these only two survive, one with progressive scleroderma, and the other with bronchiolitis obliterans. Chronic GVHD with associated infection (most commonly disseminated fungal infection) was a major contributor to mortality in all cases. Overall, after initiation of thalidomide, the 2-year Kaplan–Meier survival was 41% (95% C.I. 24%–59%). We conclude that thalidomide is a useful and well-tolerated therapy for patients with previously treated refractory chronic GVHD, including those with progressive onset of chronic GVHD, recipients of unrelated donor marrow, and children. Earlier introduction of thalidomide as an adjunct to standard immunosuppressive therapy may lead to more frequent responses and possible better survival. Bone Marrow Transplantation (2000) 26, 865–869.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sullivan KM . Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds) Bone Marrow Transplantation Blackwell Scientific: Boston 1994 339–362
Wingard JR, Piantadosi S, Vogelsang GB et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation Blood 1989 74: 1428–1435
Sullivan KM, Witherspoon RP, Storb R et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation Blood 1988 72: 546–554
Atkinson K . Chronic graft-versus-host disease Bone Marrow Transplant 1990 5: 69–82
Field EO, Gibbs JE, Tucker DF, Hellmann K . Effect of thalidomide on the graft-versus-host reaction Nature 1966 211: 1308–1310
McCarthy DM, Kanfer E, Taylor J, Barrett AJ . Thalidomide for graft-versus-host disease Lancet 1988 ii: 1135
Heney D, Norfolk DR, Wheeldon J et al. Thalidomide treatment for chronic graft-versus-host disease Br J Haematol 1991 78: 23–27
Vogelsang GB, Hess AD, Friedman KJ, Santos GW . Therapy of chronic graft-versus-host disease in a rat model Blood 1989 74: 507–511
Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft-versus-host disease New Engl J Med 1992 326: 1055–1058
Parker PM, Chao N, Nademanee A et al. Thalidomide as salvage therapy for chronic graft-versus-host disease Blood 1995 86: 3604–3609
Rovelli A, Arrigo C, Nesi F et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children Bone Marrow Transplant 1998 21: 577–581
Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome Blood 1990 75: 1024–1030
Weisdorf D, Haake R, Blazar B et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation Transplantation 1991 51: 1197–1203
Atkinson K, Horowitz MM, Gale RP et al. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease Bone Marrow Transplant 1989 4: 247–254
Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients Am J Med 1980 69: 204–217
Jakeman P, Smith WC . Thalidomide in leprosy reaction Lancet 1994 343: 432–433
Horowitz SB, Stirling AL . Thalidomide-induced toxic epidermal necrolysis Pharmacotherapy 1999 19: 1177–1180
Cole CH, Rogers PCJ, Pritchard S et al. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation Bone Marrow Transplant 1994 14: 937–942
Mehta P, Kedar A, Graham-Pole J et al. Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature Pediatrics 1999 103: e44
Acknowledgements
This work was supported in part by grants (CA 21737 and IPO1CA65493–01) from the National Cancer Institute.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Browne, P., Weisdorf, D., DeFor, T. et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 26, 865–869 (2000). https://doi.org/10.1038/sj.bmt.1702626
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702626
Keywords
This article is cited by
-
Understanding and treatment of cutaneous graft-versus-host-disease
Bone Marrow Transplantation (2023)
-
Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
Bone Marrow Transplantation (2021)
-
Phase-1/-2 study of pomalidomide in chronic GvHD
Bone Marrow Transplantation (2016)
-
Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?
Bone Marrow Transplantation (2013)
-
Therapeutic effects of thalidomide in hematologic disorders: a review
Frontiers of Medicine (2013)